Skip to main navigation Skip to search Skip to main content

An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer

  • Bastiaan M. Privé*
  • , Constantijn H.J. Muselaers
  • , Inge M. van Oort
  • , Marcel J.R. Janssen
  • , Steffie M.B. Peters
  • , Willemijn A.M. van Gemert
  • , Maike J.M. Uijen
  • , Melline M.G. Schilham
  • , J. P.Michiel Sedelaar
  • , Harm Westdorp
  • , Niven Mehra
  • , Martin Gotthardt
  • , Jelle O. Barentsz
  • , Winald R. Gerritsen
  • , J. Alfred Witjes
  • , James Nagarajah
  • *Corresponding author for this work
  • Radboud University Medical Center
  • Department of Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.

Original languageEnglish
Article number863101
JournalFrontiers in Nuclear Medicine
Volume2
DOIs
Publication statusPublished - 3 May 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2022 Privé, Muselaers, van Oort, Janssen, Peters, van Gemert, Uijen, Schilham, Sedelaar, Westdorp, Mehra, Gotthardt, Barentsz, Gerritsen, Witjes and Nagarajah.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer'. Together they form a unique fingerprint.

Cite this